JC09 (Medicine) - Exertional Heart Failure Flashcards

1
Q

Define heart failure

A

HF:

Unable to pump blood at a rate to match requirement of metabolizing tissues

Due to forward failure (adequate filling pressure) or backward failure (congestion with high filling pressure to distend myocardium for higher CO)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

S/S low cardiac output/ forward heart failure

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

S/S of right heart failure (backward HF)

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

S/S of left heart failure

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Describe the Frank Starling Law

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Mechanism of Orthopnea/ PND

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Mechanism of pulmonary edema in left heart failure

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Symptoms/ Signs of HF

  • Which ones are the most specific/ sensitive?
A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Name two criteria for Dx of heart failure

A

Framingham criteria

Boston criteria

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Name one criteria for severity of LV dysfunction

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

CXR Lung features of left heart failure

A

Upper lobe diversion/ Cephalization - pulmonary venous hypertension, pulmonary edema in the lower lobe compresses on lower lobe vessels and distends upper lobe vessels, exacerbated by hypoxia-vasoconstriction in lower lobe vessels

Kerley B lines (Septal lines) - Interstitial edema, develops at LA pressure > 15-20mmHg

Peribronchial cuffing - Interstitial fluid accumulate around bronchi causing thickening of bronchial wall, doughnut-like densities in parenchyma, LA pressure > 15-20mmHg

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Biomarkers for heart failure

Levels for severities of HF

Physiological function of the marker

A

Brain Natriuretic Peptide (BNP) and NT-proBNP

Endogenous function: BNP from cardiomyocytes to resist fibrosis and myocardial hypertrophy by decreasing BP, sympathetic tone, RAAS activation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Cardiac causes of high BNP

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Confounding/ Non-cardiac causes of high BNP

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Surgical Treatment options for HF

A

Devices:

  • Cardiac Resynchronization therapy (CRT) (biventricular pacing)
  • Cardiac assist devices: Pacemaker
  • Implantable Cardioverter Defibrillator (ICD)

Revascularization:

  • Cardiac Transplant
  • CABG for ischemic cardiomyopathy
  • Valvular surgery
  • Left ventricular assist device (LVAD)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Outline history taking questions for HF (apart from S/S)

A

Symptoms of HF: Characterize all symptoms in detail

Past history of CAD, PVD, Stroke

Etiologies:

  • Risk factors of CVS: Smoking, Metabolic syndrome (HT, DM,HL)
  • Valvular diseases: CTD, Rheumatic fever…etc
  • Systemic diseases: Thyroid storm, Pheochromocytoma …etc
  • Cardiotoxic drugs: Chemo/RT, Substance abuse

Family history:

  • Sudden death at young age, FHx of myopathies, arrhythmias, premature CVD
17
Q

First-line investigations for HF ***

A

Blood:

  • CBC
  • Serum K, Ca, PO4, glucose
  • RFT, Serum Urea and Cr
  • TSH, fT4
  • BNP, Pro-BNP

Urine microscopy and urinalysis

CXR: Features of HF

ECG

Further confirmation: CT/ MRI, Nuclear scans e.g. MIBG, Exercise/ pharmacological stress testing, Cardiac catherization

18
Q

Outline the NYHA Functional Classification to stage HF

A
19
Q

Outline the clinical course of HF over time

A
20
Q

Causes of HF

A
21
Q

Myocardial disorders that cause HF

A
22
Q

Classes of HF according to ejection fraction

A

Heart failure with Reduced Ejection Fraction (HFrEF)/ Systolic HF - LVEF <40%

Heart failure with Preserved Ejection Fraction (HFpEF)/ Diastolic HF - LVEF >50%

Other classes: HFmrEF (41-49%), HFpEF (>40%)

23
Q

Compare HFrEF and HFpEF

  • Demographics
  • Risk factors
  • Difference in CXR
A
24
Q

Approach to Dx heart failure

A
  1. Clinical diagnosis by S/S and diagnostic criteria
  2. Unclear clinical diagnosis >> use BNP or Pro-BNP concentration with clinical context to Dx
25
Q

Causes of acute HF

A

Respiratory causes:

  • Acute respiratory failure
  • Pulmonary embolism

Circulation emergency:

  • Cardiogenic shock
  • Hypertension emergency/ Malignant hypertension

Cardiac causes:

  • Acute Coronary syndrome/ MI
  • Arrhythmia
  • Acute mechanical cause e.g. VHD, LVOTO

Systemic:

  • Anemia
  • Endocrine: e.g. thyroid storm, pheochromocytoma
  • Adverse drug effects
26
Q

Approach to treat hemodynamic profiles of heart failure *

A

Congestion (both left or right heart) (Yes or No) >> S3, peripheral edema, orthopnea and PND, high JVP, Pulmonary edema

Perfusion (Adequate or poor) >> low peripheral temp and pulse

HF with congestion (Wet profile)

  1. Adequate peripheral perfusion - Wet and Warm - Treat hypertension and congestion with Vasodilators, Diuretics
  2. Poor peripheral perfusion - Wet and Cold - Inotropes, Vasopressors, Diuretics for low SBP; Vasodilators, Diuretics for normal SBP

HF without congestion (Dry profile)

  1. Adequate peripheral perfusion - Dry and warm - Compensated HF, adjust medication
  2. Poor peripheral perfusion - Dry and cold - treat hypoperfusion with Fluid Challenge, Inotropic agent
27
Q

General management and monitoring metrics for acute HF

A

General:

  • Bed rest
  • O2 supplementation: NIV, NI-cPAP, Intubation, Mech. ventilation
  • Low salt diet
  • Fluid restriction

Monitor:

  • Vitals: Orthostatic BP, O2 saturation, HR
  • Fluid I/O, Weight
  • Clinical: signs of peripheral congestion, symptoms of HF
  • Electrolytes and renal function
28
Q

Drug management of acute HF

All options

A

BP Stable:

  • IV Frusemide (diuretic)
  • IV nitrate
  • Morphine (pain)

BP unstable or deterioration:

  • Moderate: Inotropes: Dopamine and Dobutamine
  • Severe: Intra-aortic balloon pump, ECMO
29
Q

Drug management for CHRONIC HF (HFrEF)

All options

A

4 main pillars:

  1. ACEi/ ARB + Beta Blocker
  2. Mineralocorticoid receptor antagonist
  3. Angiotensin receptor neprilysin inhibitor (ARNI), Ivabradine
  4. Surgical: e.g. Cardiac resynchronization therapy (CRT)

Additional:

  • Nitrate + Hydralazine if cannot tolerant ACEi and ARB
  • Diuretics for volume overload
  • Anti-coagulants, Digoxin, PCI for A-fib
  • CABG/ PCI for CAD
30
Q

Examples of ACEi and ARB

Indications for HF

A

ACEi - Captopril, Ramipril

Recommended for all HFrEF patients

ARB - Valsartan, Losartan

For ACEi refractory patients with intractable cough, angioedema

31
Q

Effect of Beta blocker in HF

A

Cardioprotective effect, block SNS stimulation

Short-term decrease contractility, increase EF gradually after 1-3 months of use

Increase the dose with time

Long-term symptomatic improvement

32
Q

Effect of MRA on HF

A

Spironolactone - reduce HF mortality and morbidity

Eplerenone - reduce MI, HF mortality with less hormonal side effects e.g. gynaecomastia

33
Q

Effect of Ivabradine on HF

A

Funny Channel blocker - reduces SA node firing frequency and slows HR

For patients intolerant to Beta-blockers

34
Q

Treatment options for CHRONIC HF HFpEF/ Diastolic HF**

A

SGLT-2 inhibitor + ACEi/ ARB = major drugs

Additional:

  • Slow HR, BP control: BB, CCB
  • Diuretics for volume overload
  • CAD - coronary revascularization